This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk01: Hello and welcome to the Hangar's first quarter 2022 earnings conference call. My name is Juan and I will be coordinating the call today. At this time, all participants are in listen-only mode. Later, we will conduct a question and answer session. To ask a question at that time, please press star followed by number one on your telephone keypad. I will now hand over to your host, Acer Duhos, Managing Director of WestWake, to begin. So, Acer, please go ahead when you're ready.
spk05: Good morning and welcome to Hanger's first quarter 2022 earnings conference call. With us today are Vinit Asar, Hanger's President and Chief Executive Officer, and Thomas Corrale, Executive Vice President and Chief Financial Officer. Some of the information discussed today will include forward-looking statements in the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risk uncertainties that can cause Hanger's actual results to materially differ from those that we discussed today. Those risks include Among other things, matters that we have identified in our forward-looking statement portion of our latest earnings call and in our filings with the SEC. Hanger disclaims any obligation to update forward-looking information discussed on this call. And now, I'll hand the call over to Vinit.
spk06: Thank you, Asher. Good morning, and thank you all for joining Hanger's first quarter 2022 earnings call. Joining me on today's call is Tom Corrale, Hanger's Chief Financial Officer. This morning, I would provide some high level thoughts on our first quarter 2022 results, followed by an update on our business segment and operational performance. Tom will then discuss our financial results in more detail, after which we will open the call for questions. We finished Q1 with a solid top line performance, despite starting the year facing the remnants of the Omicron surge and its effect on our operations. You will recall that the first six weeks of the year, were significantly impacted by COVID-related disruptions, which subsided towards the end of the quarter. First quarter revenue of $261.3 million reflected a strong top line growth of 10%. Our adjusted EBITDA of $8.9 million was impacted by a couple of short-term items that I'll get into in a minute. A few things I'd like to note about our quarterly results. First, a solid 6.9% same clinic revenue performance in our patient care segment and an overall 10% revenue growth has given us a strong start to the year. It reflects the efforts put in by our teams around the country that navigated a difficult operating environment, especially during the first half of Q1. We were pleased to see these results, which reflect continued recovery and return of patient volumes in our clinics. It is important to note that the strong revenue growth in Q1 this year compared to Q1 of last year was achieved despite the abnormally low revenue disallowance rate we had experienced last year. Tom will provide more color on the impact of this on our adjusted EBITDA comparisons in his prepared remarks. Second, as part of our supply chain strategy, we relocated one of our largest central fabrication centers into a purpose-built state-of-the-art 49,000 square foot central fabrication center in Phoenix. This new facility includes lean manufacturing, training, and automation areas consisting of digital carvers, 3D printers, and a robotic cell. This move, which experienced a delay during the quarter due to local permitting issues, is now fully operational and will be extremely beneficial to our operations on a go-forward basis. Third, the impact of Omicron was especially significant in the first half of Q1, driven by elevated levels of sick leave during this period. The combination of this staffing shortage as well as the temporary disruption caused by the delay of our fabrication center move required an extensive use of higher cost third party fabrication and temporary labor during this time. We expect the impact of these issues to subside in Q2. Fourth, during the quarter, despite the effects of Omicron, we were able to both deliver on the work in process that had built up at December 31st, as well as replenish our WIP balance to levels significantly higher than those we carried last year at this time. This sets the stage for continued positive growth trends in Q2. Lastly, as some of you know, the first quarter is seasonally the lowest contributing quarter for our business. and shouldn't be used to extrapolate our performance for the full year. We expect earnings growth in the second quarter to accelerate, which follows our normal seasonality. Now I'll drill down into the results of our two business segments. During the first quarter, patient care revenue increased 12.3% year over year, driven by 6.9% same clinic revenue growth. Our prosthetics business in this segment edged up to 52.1% of our portfolio, up from 51.7% compared to the same quarter in the prior year. On a same clinic basis, we were also pleased to see prosthetics revenue grow 7.7% in Q1 this year versus 2021. Products and services revenues of $41.5 million for the quarter remained largely in line with the prior year. While revenues in the distribution segment were slightly higher than the same period of 2021, we did see a margin degradation in the business driven by freight, the normalization of bad debt, and other operating costs. Our therapeutic solutions business showed a slight decline in revenues, mirroring the pressures faced by their skilled nursing customers and their reduced census. Overall, when we look at our results, we feel our first quarter patient care revenue growth of 12.3%, which constituted 84% of our revenues this quarter, establishes a solid foundation for the year as we return to normalcy. With regards to our progress on tuck-in acquisitions, we closed on one transaction during Q1, and our M&A pipeline remains robust as we expect deal activity to continue through the year. Our capital deployment strategy is diligent and balanced, as we look to grow and add to our business in an accretive manner, while also looking to reduce our leverage ratio as we keep a close eye on the interest rate environment. During our last update in early March, we discussed a number of strategic initiatives and clinical studies which highlight their importance and value creation for Hanger. We continue to push forward with these initiatives as we are convinced that this will help drive mindshare and incremental business over the long run. Separately, in early April, we published a new ESG report, which highlights the initiatives and processes underway as part of our ESG journey. Given the combination of our values and the purpose-based nature of what we do, Hanger's ESG philosophy aligns naturally with and is intended to support our core business strategy. You can access our ESG report at hanger.com. With regards to our full year 2022 guidance, given our solid revenue trends and strong patient volumes, we are maintaining our full year outlook. Before I turn the call over to Tom to discuss our first quarter financial results, I want to thank our entire organization for their hard work and dedication that enabled us to generate these results. Together, we will continue to focus forward and unleash the full potential of Hanger, building on our efforts over the last several years while gaining share and providing the highest quality care for patients and customers. I want to thank everyone on the call for your interest and anger. And with that, I turn the call over to Tom, who will provide more details on our financial results and guidance. Tom.
spk04: Thanks, Vinit, and good morning. We are pleased to be off to a solid start from a revenue growth perspective with strong same-planet growth and continuing increases in the company's work and process balances. During my portion of the call, I'll provide you with additional insight into the inherent strength and sustainability of that growth, and we'll also spend some time reviewing the items in the period that had a bearing on the company's reported earnings. As Vinit shared, the patient care segment reported 12.3% total growth and 6.9% same clinic growth during the quarter. These results are even more impressive considering the abnormally low rate of disallowances in the previous year period. Our total disallowance rate was 4.4% in the first quarter of this year. This compares with a rate of 2.9% reported during the same period last year. As we discussed during last year's first quarter call, we felt that the low disallowances at that time may have reflected a COVID-19 related benefit. and were likely to return to this more normal trend, as they have. This period-over-period swing in disalloweds resulted in approximately $3.5 million in lower net revenue and earnings in the first quarter of 2022, as compared with the first quarter of 2021. In analyzing this further, as of the end of March, total disallowed revenue was 4.3% on a trailing 12-month basis. which is in line with what we reported in the first quarter. However, it's also important to point out that underlying same clinic disallowances were 3.7% in the quarter and have generally been running about 35 basis points lower than total disallowances during the past 12 months as acquisitions join us with an inherently higher rate of disallowed revenue prior to their integration. Based on this, We believe it's reasonable to expect that disallowed revenue could decrease to approximately 4% as acquisitions are integrated into the company and they gravitate to our underlying core rate. Additionally, in looking at the patient care segment 6.9% same clinic rate of growth, if you adjust for the swing in disallowances, the underlying same clinic growth rate during the first quarter was 7.9%. We estimate that approximately 2.7% related to rate and 5.2% related to volume growth. In addition to a strong rate of growth in the period, the patient care segment has also experienced further significant increases in patient demand as evidenced by a 16% increase in same clinic work and process inventory as compared with March 31st, 2021. These results are made all the more remarkable by the fact that Hanger encountered significant adversity from the Omicron variant during the first months of the quarter and experienced higher employee sick time. Despite this, our clinics were able to deliver for our patients in the quarter and entered the second quarter with an increased level of width. Before I turn to earnings, I should note that the net revenue in our products and services segment was essentially consistent with the level reported during the first quarter of 2021. We did experience modest $700,000 in growth in our distribution services net revenue that was offset by a million dollar decline in therapeutic solutions revenues. Overall, Hanger grew revenues by 23.8 million or 10% during the quarter. Now, let's turn to the company's earnings for the quarter. In total, the company produced $8.9 million in adjusted EBITDA in the first quarter, which reflected a $4.6 million decline from the same period in 2021. Patient care accounted for $1.9 million of this decrease. Products and services constituted $2 million, and the remaining $700,000 related to increases in corporate expenses. In reviewing these results, it's important to note that due to the seasonality of our business, the unique nature of the events that affected operations in the first quarter, and an inherently fixed cost structure, Hanger's first quarter earnings have always been highly volatile and are not a useful indication of the company's performance trends for the full year. In particular, this has been the case during the last three years. In reviewing patient care results, there are three key items to take into consideration. First, 3.5 million of the earnings variance relates directly to the swing from a favorable 2.9% disallowance rate in the first quarter of 2021 to a more normal rate of 4.4% in the first quarter of 2022. Secondly, as Bennett shared, given the effects of COVID-19 on our personnel, and the delay in the opening of our Phoenix, Arizona fabrication facility in January, we found it necessary to increase our reliance on higher-cost, third-party fabrication providers. Due to these costs, our total fabrication network expenses increased on a percent of revenue basis and drove $1.2 million in higher operating costs, with $900,000 affecting adjusted EBITDA. This was a primary driver of the increase experienced in material costs during the quarter. The use of third-party fabrication returned to more normal levels by March after COVID subsided and our new facility was opened. We chose to meet the needs of our patients during the quarter despite these adversities and to bear these additional costs in the process. Finally, an additional cost item that affected our materials costs in the patient care segment during the quarter related to $630,000 in increased freight costs, primarily relating to increased fuel and container costs. While we do not necessarily view this particular item to be temporary, we currently believe that favorable reimbursement rate trends as compared to our original forecast will enable us to more than offset it. In total, these three items affected comparative patient care adjusted EBITDA results by 5 million. of which only the 630,000 in freight was not transitory in nature. Another important point is that absent the transitory items and the acquisition effects on the comparative periods, patient care's underlying margin in Q1 2022 was the same as its margin in Q1 2021. In other words, after taking these and other smaller variances into consideration, During the quarter, inflation in material costs and salaries was generally consistent with the patient care segment's underlying increase in reimbursement rate. During 2021 and for the year to date, Hanger has been able to manage underlying inflation. In the case of material costs, this has been due primarily to our purchasing scale, ability to emphasize preferential SKUs, and the investment we've made in advancing our supply chain operations. In the case of labor costs, while we have encountered some constraints in the areas of office administration, technician, and distribution center roles, these are a relatively smaller and lower compensated portion of our employee base. In contrast to other healthcare firms you may be more familiar with, Hanger does not employ nurses and has accordingly not had to endure the significant cost increase you've heard about in the hospital and related sectors. As a result of these factors, to date, patient care has not experienced a notable change in its margin due to inflation. In turning to the products and services segment, in a manner similar to patient care, comparative results for this segment also reflect some items that were beneficial to the first quarter 2021 results, as well as items specific to Q1 2022. However, as Vinit shared, we have experienced a decrease in the underlying margin of this portion of our business. Fortunately, we anticipated much of this in our plan for the year. In summarizing the company's total earnings performance during the quarter, in recent years, Hanger's first quarter adjusted EBITDA as a percentage of the total year has ranged from 5% to 10% of full year results. Given the strong same clinic rate growth rates being achieved and the inherent nature of the items that cause volatility to earnings, we believe 2022 will follow this same pattern. Now I'll spend a few minutes on the company's cash flows. Due to seasonality in the payment of annual incentive compensation, Hanger normally consumes operating cash flow in the first quarter. This year, due to lower incentive payments, lower accounts payable consumption, and decreases in cash outflows for inventory, we consumed 34.1 million less operating cash flow during the first quarter of 2022 as compared with the first quarter of 2021. Capital expenditures and purchases of therapeutic equipment were also favorable to trend as we expanded just 4.5 million in the current year as contrasted to 6.9 million in the prior year. On a trailing 12 months basis, our capital expenditures have run 22.4 million. As of March 31st, 2022, we had 167.2 million in total liquidity, which is up by 2.1 million as compared to March 31st, 2021. We are currently sitting with a leverage ratio of 3.7 times the midpoint of our 2022 guidance. In closing, I'll provide a few comments regarding our outlook for 2022. As we progress through the second quarter, we are highly encouraged by the strong rates of same clinic revenue growth and increases in work in process reflected in our results. We currently believe those trends are more than sufficient to offset the structural cost items that were not specific to the quarter, such as freight costs, as well as the trends in our products and services segment. Given these factors, we are maintaining our original outlook at this time. As we originally announced on February 7th, we estimate that 2022 net revenue will be in a range between $1.19 billion to $1.22 billion, and adjusted EBITDA will be in a range between $127 million to $132 million. Overall, patient care revenue growth will be aided by approximately $35 million in the annualized revenue effect of acquisitions completed in 2021. With that, I'll turn the call back over to the operator to open it up for any questions that you may have.
spk01: Thank you. If you would like to ask a question at this point, please press the star followed by number one on your telephone keypad. If you would like to withdraw your question, please press the star followed by number two. When preparing to ask a question, please ensure your phone is unmuted locally. And the first question comes from the line of Brian Tackley from Jefferies. Please, Brian, your line is now open.
spk02: Hey, good morning, guys. Thanks for the questions here. So I guess, Tom, my first question, as I think about, you know, the non-recurring or what feels like transient issues during the quarter, maybe just give us a little more color, you know, like how does that work out or how did that play out with the use of the third-party fabs? Because normally when we see When we see quarantines of employees, it's the top line where that hits, you know, in terms of capacity. So, you know, just maybe if you can explain how that all played out and what you're seeing currently in terms of the utilization of third parties.
spk04: Yeah, Brian. So normally Hanger does use third parties for certain of its fabrication. And in the first quarter, we found that we just had to use significantly more because of the disruption in our own operations. It really didn't affect revenues. I think you can see revenues are very robust because we were able to deliver for patients, but it did affect our expenses because we had to rely on these third-party FABs in addition to carrying the overheads associated with the employees that we were unable to use.
spk02: Gotcha. No, I appreciate that. And then, you know, you maintain guidance, obviously, and I guess the Yeah, I get the top line driven confidence there, but maybe just, you know, anything you can share with us that would give us confidence in the numbers that you're maintaining today. You know, I know that obviously there's a high contribution margin to revenue. So just thought, you know, if you can share with us anything that any color that you can share that would give us that level of confidence.
spk06: Sure. Yeah. You know, the first one is, The first quarter revenues, you know, clearly came in strong. We're really pleased with it. We've talked about some of the initiatives and programs we've put in place over the last couple of years, and we see them bearing fruit right now. So, you know, we feel very good about the top line. And as Tom mentioned in his prepared remarks, that the whip ending the first quarter also was pretty strong. So, you know, for the remainder of the year, we're feeling pretty good about the top line growth. And then when you combine that with these couple of transitory items, it's really two transitory items that affected Q1. It's the swing in the disallowance rate, which was abnormally low last year, and then it's these higher third-party FAB spend in Q1 of this year. When you adjust for all of that, we're feeling very good about where we are.
spk02: Got it. And then, Tom, just to clarify, you don't have acquisitions in the guidance, right?
spk04: That's correct. We have only the 2021 acquisitions, you know, the effect on revenue this year. It's not comparable to the prior year, which is around $35 million. So anything we close in 2022 would be something that we would eventually have to adjust guidance for. All right. Got it. Awesome. Thank you.
spk06: Thanks, Brian.
spk01: Thank you. Our next question comes from the line of Larry Solo from CJS Securities. Please, Larry, your line is now open.
spk03: Great. Good morning, guys. Picking up on just Brian's line of thinking on the acquisitions, maybe you could discuss the pipeline of opportunities. I feel like during COVID the last couple of years, maybe there are more companies who could use a larger, bigger hand for help. And then how do you weigh sort of your longer-term goals maybe to bring down your leverage a little bit It seems like you're generating, it looks like the last 12 months, about $50 million in free cash flow, which is a solid number. But I don't see that number really growing that much above that. How do you sort of take that $50 million in free cash flow, maybe the idea of trying to reduce your leverage a little bit, mixing that with the opportunities on the acquisition front? Thanks.
spk06: Sure, Larry. I'll take the first part of the question, and then Tom can pick up on the second part. In terms of the acquisition pipeline, as we had mentioned, we closed on one deal in the first quarter. We're feeling great about the pipeline, especially because we're able to have conversations now with a lot of O&P independent providers that do want to partner with us, and we're able to actually pick out and partner with those that are stronger than others. You know, today I don't think there's a dearth of opportunities out there. We're just being very selective in who we partner with. We have a very strict criteria. We want to make sure that, you know, outside of the obvious financials and the geography, we also make sure the cultural fit is there, the compliance issues. So when we take all of this into account, you know, we are able to be selective and we have a solid pipeline there.
spk04: And, you know, when you look at it, Larry, you know, the underlying $50 million of trailing 12 months free cash flow, you know, we should point out that much of that period was during a COVID-affected, you know, period of operations. And as our earnings increase, you know, with capital expenditures running, you know, favorable to our forecast down in the $20 to $25 million range, we do think there's some opportunity to see some increased free cash flow in the company, which some of which we could potentially use to address, you know, that underlying leverage question.
spk01: Okay.
spk03: Okay. Okay. Fair. And then just another question, just sort of a higher level, long-term question. You guys have a lot of multiple initiatives and certainly differentiating yourself from probably all the other providers out there. And I think in your last update in your annual report, you certainly look like you've taken some market share, at least through the acquisition side of the story. Do you feel like you're taking share? I know it's sort of a hard way to look at this. There probably aren't many, you know, not great, you know, data on, you know, aggregate data on the industry. But do you feel like, you know, is there a way to kind of look and see if you're actually growing faster than the industry and actually taking share from competitors? Because it does seem like qualitatively you're doing you know, a lot of things that are much better, more value add to patients and doctors alike.
spk06: Yeah, Larry, you know, on both fronts, on the organic front and the inorganic front, we believe we're taking a share on the inorganic front. It's pretty obvious, you know, as these businesses join us. But on the organic side, you know, when you look at our same clinic numbers, you know, especially this quarter and in the prior year, it's clear that we are growing faster than the market. If you look at the market growth of 2% to 3%, depending on pre-COVID or during COVID, irrespective, on the same clinic basis, we know we're growing faster than the market and picking up market share. And you're right, it goes back to all the different investments and differentiators we put in place over the last few years, whether it's clinical outcomes, whether it's our revenue cycle management, whether it's our supply chain, our leadership, So, you know, we feel very good about picking up market share on both fronts, organic and inorganic.
spk03: Okay. Great. I appreciate that call. Thanks, guys.
spk06: Thanks, Larry.
spk01: Thank you. We have another question from the line of Brian Tankley from Jefferies. Please, Brian, your line is now open.
spk02: Hey, guys, thanks for letting me ask. I guess, Tom, you know, you mentioned how Q1 is normally your weakest even at quarter, 5% to 10% total. But any thoughts you can share with us on how we should be thinking about the cadence for earnings for this year, given some of the challenges that you've seen, but also the strong top line and pipeline expectation?
spk04: Yeah, I mean, when you look at the overall cadence, Brian, in past years, you know, I think it can serve as a pretty indicative indicator way to think about the current year. You know, typically the first quarter, as we said, 5 to 10 percent. You know, when you go to the fourth quarter, we're typically, you know, 30 to 35, you know, 36 percent. And so it's a big swing from Q1 to Q4 with the intervening quarters being probably a bit more ratable, you know, in terms of the way that you look at them on a percent of earnings basis. So I think our historical trends really serve as a good foundation for thinking about the current year.
spk06: All right, got it. Thank you. Thanks, Brian.
spk01: Thank you. We currently have no further questions, so this concludes today's conference call. Thank you so much for joining. You may now disconnect your lines.
Disclaimer